Abstract |
We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.
|
Authors | Thomas J Montine, Creighton H Phelps, Thomas G Beach, Eileen H Bigio, Nigel J Cairns, Dennis W Dickson, Charles Duyckaerts, Matthew P Frosch, Eliezer Masliah, Suzanne S Mirra, Peter T Nelson, Julie A Schneider, Dietmar Rudolf Thal, John Q Trojanowski, Harry V Vinters, Bradley T Hyman, National Institute on Aging, Alzheimer’s Association |
Journal | Acta neuropathologica
(Acta Neuropathol)
Vol. 123
Issue 1
Pg. 1-11
(Jan 2012)
ISSN: 1432-0533 [Electronic] Germany |
PMID | 22101365
(Publication Type: Journal Article, Practice Guideline, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Alzheimer Disease
(pathology)
- Brain
(pathology)
- Cerebrovascular Disorders
(classification, pathology)
- Cerebrovascular Trauma
(classification)
- DNA-Binding Proteins
(metabolism)
- Hippocampus
(pathology)
- Humans
- Lewy Body Disease
(classification, pathology)
- National Institute on Aging (U.S.)
- Sclerosis
(classification)
- United States
|